Founded in 2015, Edesa Biotech brings innovative new treatments for dermatological and anorectal diseases. Late-stage prescription drugs developed by Edesa Biotech aim to help patients who experience limited treatment options. Edesa Biotech's focus on dermatology is led by an experienced team that have licensed global rights to clinical stage assets for dermatology and anorectal indications.
Location: Canada, Ontario, Markham
Employees: 11-50
Total raised: $32.115482M
Founded date: 2015
Investors 1
| Date | Name | Website |
| - | Lumira Ven... | lumiravent... |
Funding Rounds 3
| Date | Series | Amount | Investors | Deal News |
| 12.10.2023 | - | $16.806477... | - | lumiravent... |
| 02.02.2021 | - | $10.949005... | - | lumiravent... |
| 06.01.2020 | - | $4.36M | - | lumiravent... |
Mentions in press and media 23
| Date | Title | Description | Source |
| 12.10.2023 | Edesa Biotech to Receive Up To C$23 Million in Funding from ... | Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on inflammator... | lumiravent... |
| 10.02.2023 | Edesa Biotech Reports Fiscal 1st Quarter 2023 Results | TORONTO, ON / ACCESSWIRE / February 10, 2023 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage b... | accesswire... |
| 10.02.2023 | Edesa Biotech Reports Fiscal 1st Quarter 2023 Results | TORONTO, ON / ACCESSWIRE / February 10, 2023 / Edesa Biotech, Inc. EDSA, a clinical-stage biopharmac... | einpresswi... |
| 16.12.2022 | Edesa Biotech Reports Fiscal Year 2022 Results | TORONTO, ON / ACCESSWIRE / December 16, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage b... | accesswire... |
| 12.08.2022 | Edesa Biotech Reports Fiscal 3rd Quarter 2022 Results | Phase 3 ARDS drug study in hospitalized Covid-19 patients expanded Company reaffirms guidance on com... | accesswire... |
| 11.07.2022 | Edesa Biotech to Present at ARDS Drug Development Summit | TORONTO, ON / ACCESSWIRE / July 11, 2022 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage bioph... | accesswire... |
| 19.05.2022 | Edesa Biotech to Present at H.C. Wainwright Global Investmen... | TORONTO, ON / ACCESSWIRE / May 19, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopha... | accesswire... |
| 13.05.2022 | Edesa Biotech Reports Fiscal 2nd Quarter 2022 Results | TORONTO, ON / ACCESSWIRE / May 13, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopha... | accesswire... |
| 28.04.2022 | Edesa Biotech Reports Dermatitis Study Enrolling Faster than... | Completion of enrollment is anticipated by calendar fourth quarter for the Phase 2b study of Edesa's... | accesswire... |
| 24.03.2022 | Edesa Biotech Announces Closing of $10.0 Million Registered ... | TORONTO, ON / ACCESSWIRE / March 24, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biop... | accesswire... |
Show more